Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis
Open Access
- 11 August 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (2), 120-128
- https://doi.org/10.1093/eurheartj/ehu292
Abstract
Up to 40% of ischaemic strokes are cryptogenic. A strong association between cryptogenic stroke and the prevalence of patent foramen ovale (PFO) suggests paradoxical embolism via PFO as a potential cause. Randomized trials failed to demonstrate superiority of PFO closure over medical therapy. Randomized trials comparing percutaneous PFO closure against medical therapy or devices head-to-head published or presented by March 2013 were identified through a systematic search. We performed a network meta-analysis to determine the effectiveness and safety of PFO closure with different devices when compared with medical therapy. We included four randomized trials (2963 patients with 9309 patient-years). Investigated devices were Amplatzer (AMP), STARFlex (STF), and HELEX (HLX). Patients allocated to PFO closure with AMP were less likely to experience a stroke than patients allocated to medical therapy [rate ratio (RR) 0.39; 95% CI: 0.17–0.84]. No significant differences were found for STF (RR 1.01; 95% CI: 0.44–2.41), and HLX (RR, 0.71; 95% CI: 0.17–2.78) when compared with medical therapy. The probability to be best in preventing strokes was 77.1% for AMP, 20.9% for HLX, 1.7% for STF, and 0.4% for medical therapy. No significant differences were found for transient ischaemic attack and death. The risk of new-onset atrial fibrillation was more pronounced for STF (RR 7.67; 95% CI: 3.25–19.63), than AMP (RR 2.14; 95% CI: 1.00–4.62) and HLX (RR 1.33; 95%-CI 0.33–4.50), when compared with medical therapy. The effectiveness of PFO closure depends on the device used. PFO closure with AMP appears superior to medical therapy in preventing strokes in patients with cryptogenic embolism.Keywords
This publication has 34 references indexed in Scilit:
- Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic StrokeThe New England Journal of Medicine, 2013
- Percutaneous Closure of Patent Foramen Ovale in Cryptogenic EmbolismThe New England Journal of Medicine, 2013
- Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen OvaleThe New England Journal of Medicine, 2012
- Long-Term Propensity Score–Matched Comparison of Percutaneous Closure of Patent Foramen Ovale With Medical Treatment After Paradoxical EmbolismCirculation, 2012
- Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closureCatheterization and Cardiovascular Interventions, 2011
- Comparison of Three Patent Foramen Ovale Closure Devices in a Randomized Trial (Amplatzer Versus CardioSEAL-STARflex Versus Helex Occluder)The American Journal of Cardiology, 2008
- Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devicesThe American Journal of Cardiology, 2004
- Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patientsJournal of the American College of Cardiology, 2004
- Infarcts of undetermined cause: The NINCDS stroke data bankAnnals of Neurology, 1989
- Prevalence of Patent Foramen Ovale in Patients with StrokeNew England Journal of Medicine, 1988